Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study

Michael Jonathan Kucharczyk, James Man Git Tsui, Farzin Khosrow-Khavar, Boris Bahoric, Luis Souhami, Maurice Anidjar, Stephan Probst, Ahmad Chaddad, Paul Sargos, Tamim Niazi, Michael Jonathan Kucharczyk, James Man Git Tsui, Farzin Khosrow-Khavar, Boris Bahoric, Luis Souhami, Maurice Anidjar, Stephan Probst, Ahmad Chaddad, Paul Sargos, Tamim Niazi

Abstract

Purpose: Following radical prostatectomy, prostate bed radiotherapy (PBRT) has been combined with either long-term androgen deprivation therapy (LT-ADT) or short-term ADT with pelvic lymph node radiotherapy (PLNRT) to provide an oncological benefit in randomized trials. McGill 0913 was designed to characterize the efficacy of combining PBRT, PLNRT, and LT-ADT. It is the first study to do so prospectively. Methods: In a single arm phase II trial conduced from 2010 to 2016, 46 post-prostatectomy prostate cancer patients at a high-risk for relapse (pathological Gleason 8+ or T3) were assessed for treatment with combined LT-ADT (24 months), PBRT, and PLNRT. Patients received PLNRT and PBRT (44 Gy in 22 fractions) followed by a PBRT boost (22 Gy in 11 fractions). The primary endpoint was progression-free survival (PFS). Toxicity and quality of life (QoL) were evaluated using CTCAE V3.0 and EQ-5D-3L questionnaires, respectively. Results: Among the 43 patients were treated as per protocol, median PSA was 0.30 μg/L. On surgical pathology, 51% had positive margins, 40% had Gleason 8+ disease, 42% had seminal vesicle involvement, and 19% had lymph node involvement. At a median follow-up of 5.2 years, there were no deaths or clinical progression. At 5 years, PFS was 78.0% (95% Confidence Interval 63.7-95.5%). Not including erectile dysfunction, patients experienced: 14% grade 2 endocrine toxicity while on ADT, one incident of long-term gynecomastia, 5% grade 2 acute urinary toxicity, 5% grade 2 late Urinary toxicity, and 24% long-term hypogonadism. No comparison between the average or minimum self-reported QoL at baseline, during ADT, nor after ADT demonstrated a statistically significant difference. Conclusions: Combining PBRT, PLNRT, and LT-ADT had an acceptable PFS in patients with significant post-operative risk factors for recurrence. While therapy was well-tolerated, long-term hypogonadism was a substantial risk. Further investigations are needed to determine if this combination is beneficial. Trial registration: NCT01255891.

Keywords: adjuvant; androgen deprivation therapy (ADT); clinical trial; pelvic lymph node radiotherapy; prostate cancer; radiotherapy; salvage.

Copyright © 2020 Kucharczyk, Tsui, Khosrow-Khavar, Bahoric, Souhami, Anidjar, Probst, Chaddad, Sargos and Niazi.

Figures

Figure 1
Figure 1
Kaplan Meier analysis of the progression-free survival. Progression was defined as either biochemical (prostate specific antigen nadir + 0.2 μg/L) or clinical progression on exam or imaging.
Figure 2
Figure 2
Boxplots illustrating the medians, interquartile ranges, and ranges of QoL reported by individual study participants at baseline, during ADT, and anytime following ADT. (A) Comparison of the averaged self-reported QoL. (B) Comparison of lowest self-reported QoL. ADT, androgen deprivation therapy; QoL, quality of life.

References

    1. Christian Carrie NM, Burban-Provost P, Paul S, Igor L, Stephane S, Yazid B, et al. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475). J Clin Oncol. (2019) 37:5001 10.1200/JCO.2019.37.15_suppl.5001
    1. Pollack A, Karrison TG, Balogh AGJr, Low D, Bruner DW, Wefel JS, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. Int J Radiat Oncol Biol Phys. (2018) 102:1605 10.1016/j.ijrobp.2018.08.052
    1. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. (2017) 376:417–28. 10.1056/NEJMoa1607529
    1. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. (2015) 16:320–7. 10.1016/S1470-2045(15)70045-8
    1. Ray GR, Bagshaw MA, Freiha F. External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol. (1984) 132:926–30. 10.1016/S0022-5347(17)49951-4
    1. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol. (1990) 144:1180–4. 10.1016/S0022-5347(17)39686-6
    1. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol. (1994) 152:1077–81. 10.1016/S0022-5347(17)32507-7
    1. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. . Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. (2011) 59:832–40. 10.1016/j.eururo.2011.02.024
    1. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. . Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. (2014) 65:554–62. 10.1016/j.eururo.2013.09.025
    1. Michalski JM, Lawton C, El Naqa I, Ritter M, O'meara E, Seider MJ, et al. . Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. (2010) 76:361–8. 10.1016/j.ijrobp.2009.02.006
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international cliniscal trials in oncology. J Natl Cancer Inst. (1993) 85:365–76. 10.1093/jnci/85.5.365
    1. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. (2005) 43:203–20. 10.1097/00005650-200503000-00003
    1. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. (1997) 49:822–30. 10.1016/S0090-4295(97)00238-0
    1. Barry MJ, Fowler FJ, Jr, O'leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. (1992) 148:1549–57; discussion: 1564. 10.1016/S0022-5347(17)36966-5
    1. Program CTE. Common Terminology Criteria for Adverse Events, Version 3.0. (2006) Available online at: (accessed April 13, 2019).
    1. Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L, et al. . Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. (2005) 366:572–8. 10.1016/S0140-6736(05)67101-2
    1. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. (1982) 38:143–51. 10.2307/2530297
    1. A'hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. (2001) 20:859–66. 10.1002/sim.721
    1. Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, et al. . Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. (2007) 99:1376–9. 10.1111/j.1464-410X.2007.06844.x
    1. Richaud P. Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer. U.S. National Library of Medicine (2008). Available online : (accessed Marc 22, 2019).
    1. Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, et al. . A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int. (2014) 113(Suppl. 2):7–12. 10.1111/bju.12623
    1. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, et al. . Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol. (2018) 4:e175230. 10.1001/jamaoncol.2017.5230
    1. Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, et al. . More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol. (2015) 67:212–9. 10.1016/j.eururo.2014.05.011
    1. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. . Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. (2016) 34:3648–54. 10.1200/JCO.2016.67.9647
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. (1997) 50:683–91. 10.1016/S0895-4356(97)00049-8
    1. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'amico R, et al. . Indirect comparisons of competing interventions. Health Technol Assess. (2005) 9:1–134, iii–iv. 10.3310/hta9260
    1. Pollack A, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, et al. A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. (2004) 60:S186–7. 10.1016/j.ijrobp.2004.06.120
    1. Bolla M, De Reijke TM, Van Tienhoven G, Van Den Bergh AC, Oddens J, Poortmans PM, et al. . Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. (2009) 360:2516–27. 10.1056/NEJMoa0810095
    1. Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, et al. . Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. (2018) 74:432–41. 10.1016/j.eururo.2018.06.018
    1. Kneebone A, Fraser-Browne C, Delprado W, Duchesne G, Fisher R, Frydenberg M, et al. A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP RAVES trial. Int J Radiat Oncol Biol Phys. (2019) 105:S37–8. 10.1016/j.ijrobp.2019.06.456
    1. Parker C, Clarke NW, Cook A, Kynaston HG, Meidahl Petersen P, Cross W, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. Ann Oncol. (2019) 30(Suppl.5):v851–934. 10.1093/annonc/mdz394.042
    1. Vale CL, Brihoum M, Chabaud S, Cook A, Fisher D, Forcat S, et al. Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis. Ann Oncol. (2019) 30(Suppl.5):v851–934. 10.1093/annonc/mdz394.041
    1. Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, et al. . Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol. (2015) 33:4158–66. 10.1200/JCO.2015.63.3529
    1. Tran P. Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy. (2014). Available online at: (accessed May 28, 2019).
    1. Supiot S, Campion L, Pommier P, Dore M, Racadot S, Rio E, et al. Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: a phase I study of the GETUG/GEP. J Clin Oncol. (2017) 35:45–45. 10.1200/JCO.2017.35.6_suppl.45
    1. Armstrong AJ, Bitting RL, Healy P, George DJ, Kim S, Mayer TM, et al. Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): the STREAM trial. J Clin Oncol. (2019) 37:29–29. 10.1200/JCO.2019.37.7_suppl.29
    1. Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, et al. A phase II salvage trial of AR inhibition with ADT and apalutamide with radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR). J Clin Oncol. (2019) 37:TPS5097 10.1200/JCO.2019.37.15_suppl.TPS5097
    1. Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies. Eur Urol. (2017). 10.1016/j.eururo.2017.09.027
    1. James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. . Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol. (2016) 2:348–57. 10.1001/jamaoncol.2015.4350
    1. Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, Briganti A, et al. . Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection. Eur Urol. (2018) 74:253–6. 10.1016/j.eururo.2018.04.017
    1. Ost P, De Bruycker AL, Claeys T, Delrue L, De Meerleer G, De Vos F, et al. Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial. J Clin Oncol. (2017) 35:153–153. 10.1200/JCO.2017.35.6_suppl.153
    1. De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, et al. . Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol. (2018) 75:826–33. 10.1016/j.eururo.2018.10.044

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever